-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VFTzhDljWYgFgBP8MNlqD/9PbKZlRaU/PvbQZLJryRXJFtmfcLFWj3pBiJ6xsgXu fPoVYrEniXCS1bpW6CIyQg== 0001144204-06-006000.txt : 20060214 0001144204-06-006000.hdr.sgml : 20060214 20060214152120 ACCESSION NUMBER: 0001144204-06-006000 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051231 FILED AS OF DATE: 20060214 DATE AS OF CHANGE: 20060214 EFFECTIVENESS DATE: 20060214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 06613956 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v035531_bakerbros-13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: December 31, 2005 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. February 14, 2006 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 55 ----------- Form 13F Information Table Entry Value: 726,602 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 6,559 665,904 SH SOLE 665,904 Adolor Corp. COM 00724X102 15,569 1,066,397 SH SOLE 1,066,397 Allos Therapeutics Inc. COM 019777101 8,492 3,949,951 SH SOLE 3,949,951 Amylin Pharmaceuticals Inc. COM 032346108 69,591 1,743,274 SH SOLE 1,743,274 Anadys Pharmaceuticals Inc. COM 03252Q408 3,082 350,237 SH SOLE 350,237 Anormed Inc. COM 035910108 39,058 9,411,500 SH SOLE 9,411,500 Arena Pharmaceuticals Inc. COM 040047102 2,675 188,262 SH SOLE 188,262 Array Biopharma Inc. COM 04269X105 2,822 402,563 SH SOLE 402,563 Atherogenics Inc. COM 047439104 1,001 50,036 SH SOLE 50,036 Autoimmune Inc. COM 052776101 24 26,100 SH SOLE 26,100 Biocryst Pharmaceuticals Inc. COM 09058V103 39,263 2,344,036 SH SOLE 2,344,036 Cephalon Inc. COM 156708109 864 13,340 SH SOLE 13,340 Coley Pharmaceutical Group Inc.COM 19388P106 6,965 459,416 SH SOLE 459,416 Corcept Therapeutics Inc. COM 218352102 365 100,000 SH SOLE 100,000 Critical Therapeutics Inc. COM 22674T105 3,984 554,917 SH SOLE 554,917 Cubist Pharmaceuticals Inc. COM 229678107 15,704 739,338 SH SOLE 739,338 Curis Inc. COM 231269101 95 26,800 SH SOLE 26,800 Cytokinetics Inc. COM 23282W100 642 98,300 SH SOLE 98,300 Dynavax Technologies Corp. COM 268158102 80 18,900 SH SOLE 18,900 Genomic Health Inc. COM 37244C101 9,086 997,402 SH SOLE 997,402 GTX Inc. COM 40052B108 287 37,912 SH SOLE 37,912 Halozyme Therapeutics Inc. COM 40637H109 910 500,000 SH SOLE 500,000 Incyte Corp. COM 45337C102 17,697 3,314,070 SH SOLE 3,314,070 Inhibitex Inc. COM 45719T103 22,367 2,662,695 SH SOLE 2,662,695 Intermune Inc. COM 45884X103 11,682 695,358 SH SOLE 695,358 Intrabiotics Pharmaceuticals COM 46116T506 4,024 1,114,609 SH SOLE 1,114,609 Ithaka Acquisition Corporation COM 465707206 333 65,000 SH SOLE 65,000 Ligand Pharmaceuticals Inc. CL B 53220K207 428 38,357 SH SOLE 38,357 Medarex Inc. COM 583916101 15,432 1,114,194 SH SOLE 1,114,194 Metabasis Therapeutics Inc. COM 59101M105 8,707 1,088,354 SH SOLE 1,088,354 Monogram Biosciences Inc. COM 60975U108 872 466,419 SH SOLE 466,419 Myriad Genetics Inc. COM 62855J104 12,843 617,472 SH SOLE 617,472 Neopharm Inc. COM 640919106 5,119 474,396 SH SOLE 474,396 Neose Technologies Inc. COM 640522108 1,119 576,923 SH SOLE 576,923 Neurogen Corp. COM 64124E106 35,098 5,325,999 SH SOLE 5,325,999 Nuvelo Inc. COM 67072M301 7,243 893,064 SH SOLE 893,064 Onyx Pharmaceuticals Inc. COM 683399109 26,428 917,628 SH SOLE 917,628 Pharmacyclics Inc. COM 716933106 757 213,219 SH SOLE 213,219 Pozen Inc. COM 73941U102 5,826 607,544 SH SOLE 607,544 Renovis Inc. COM 759885106 4,590 300,000 SH SOLE 300,000 Seattle Genetics Inc. COM 812578102 5,640 1,194,927 SH SOLE 1,194,927 Senomyx Inc. COM 81724Q107 3,852 317,823 SH SOLE 317,823 Theravance Inc. COM 88338T104 9,253 410,869 SH SOLE 410,869 Trimeris Inc. COM 896263100 41,391 3,602,369 SH SOLE 3,602,369 Vertex Pharmaceuticals Inc. COM 92532F100 25,274 913,406 SH SOLE 913,406 Viropharma Inc. COM 928241108 135,266 7,311,700 SH SOLE 7,311,700 Xcyte Therapies Inc. PFD CV EXCH 98389F408 354 95,500 SH SOLE 95,500 Xenoport Inc. COM 98411C100 4,940 275,221 SH SOLE 275,221 Zymogenetics Inc. COM 98985T109 13,378 786,464 SH SOLE 786,464 Alexion Pharmaceuticals Notes 1.375% 2/01/2012 CONV BONDS 015351AF6 36,220 42,800,000 PRN SOLE 42,800,000 Decode Genetics Notes 3.5% 4/15/2011 CONV BONDS 243586AB0 2,468 3,000,000 PRN SOLE 3,000,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 14,559 19,000,000 PRN SOLE 19,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 5,280 6,000,000 PRN SOLE 6,000,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 15,069 13,500,000 PRN SOLE 13,500,000 Viropharma Incorporated Notes 6% 3/01/2007 CONV BONDS 928241AC2 5,975 5,975,000 PRN SOLE 5,975,000
-----END PRIVACY-ENHANCED MESSAGE-----